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Summary 
The role of epitope spreading in the pathology of relapsing-remitting experimental autoimmune 
encephalomyelitis (R-EAE) was examined. Using peripherally induced immunologic tolerance 
as a probe to analyze the neuropathologic T  cell repertoire, we show that the majority of the 
immunopathologic reactivity during the acute phase of R-EAE in SJL/J mice induced by active 
immunization with the intact proteolipid (PLP) molecule is directed at the PLP139-151 epitope 
and that responses to secondary encephalitogenic PLP epitopes may contribute to the later relapsing 
phases of disease. Intermolecular epitope spreading was demonstrated by showing the develop- 
ment of T cell responses to PLP139-151 after acute disease in mice in which R-EAE was initiated 
by the transfer ofT cells specific for the non-cross-reactive MBP84-104 determinant. Intramolecular 
epitope spreading was demonstrated by showing that endogenous host T cells specific for a sec- 
ondary encephalitogenic PLP epitope (PLP178-191) are demonstrable by both splenic T cell prolifer- 
ative and in vivo delayed-type hypersensitivity responses in mice in which acute central nervous 
system damage was initiated by T cells reactive with the immunodominant, non-cross-reactive 
PLP139-151 sequence. The PLP178-191-specific  responses are activated as a result of and correlate 
with the degree of acute tissue damage, since they do not develop in mice tolerized to the initi- 
ating epitope before expression of acute disease. Most importantly, we show that the PLP178- 
191-specific responses are capable of mediating R-EAE upon adoptive secondary transfer to naive 
recipient mice. Furthermore, induction of tolerance to intact PLP (which inhibits responses to 
both the initiating PLP139-151  epitope and to the PLP178-191  epitope) after the acute disease 
episode is sufficient to prevent relapsing disease. These results strongly support a contributory 
role ofT cell responses to epitopes released as a result of acute tissue damage to the immunopatho- 
genesis of relapsing clinical episodes and have important implications for the design of antigen- 
specific immunotherapies for the treatment of chronic autoimmune disorders in humans. 
t~ 
lapsing  experimental  autoimmune  encephalomyelitis 
(R-EAE) 1 is  a  CD4 +  Thl-mediated demyelinating 
disease of the central nervous system (CNS) (1) that is induc- 
ible in genetically susceptible animals by immunization with 
myelin basic protein (MBP) or proteolipid protein (PLP) (2, 3) 
or synthetic peptides corresponding to the major encephalito- 
genic epitopes of MBP and PLP (4, 5). Alternatively, R-EAE 
The first two authors contributed  equally to this work and should  both 
be considered first authors. 
1 Abbreviations used in this paper: CNS, central nervous system; DTH, 
delayed-type  hypersensitivity;  ECDI, 1-ethyl-3-(3-dimethylaminopropyl)- 
carhodiimide  HC1; MBP, myelin  basic protein; MMS, mean  maximal  dis- 
ease severity;  MS, multiple sclerosis; PLP, proteolipid protein; K-EAE, 
relapsing experimental  autoimmune  encephalomyelitis;  SP, splenocyte. 
may be transferred to naive recipients with in vitro-activated 
MBP or PLP-specific  CD4 + T  cells  (5-7).  The relapsing- 
remitting course of paralysis is characterized by a moderate 
to severe initial acute phase of disease followed by recovery 
and one or more relapses. This pattern of relapses and spon- 
taneous recovery in experimental animal models, which occurs 
over a period of weeks to months, is very similar to the clin- 
ical signs of disease observed in multiple sclerosis (MS) pa- 
tients over many years (8). 
The immunologic mechanisms involved in the induction 
and regulation of clinical relapses are unclear. Increased MHC 
class II expression has been found in the CNS of mice during 
clinical relapses (9, 10) and may influence the pattern of local 
production of pro- and antiinflammatory cytokines during 
relapses or remissions (11). Several studies have also demon- 
strated that changes occur in class II restriction and antigen 
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during the course of disease (12-15).  Thus, reactivity to neu- 
roepitopes other than that used to induce the initial clinical 
episode,  a phenomenon termed epitope spreading (16), may 
contribute to the relapsing course of clinical R-EAE. Epi- 
tope spreading has also recently been proposed to contribute 
to the pathogenesis of spontaneous autoimmune diabetes in 
the nonobese diabetic mouse (17, 18). These reports provide 
intriguing evidence that the T cell repertoire is dynamic and 
that reactivity to additional specificities  occurs during the 
course of both experimentally induced and spontaneous au- 
toimmune diseases. This is of particular interest in MS, where 
B and T cell reactivity to MBP and PLP has been observed 
(19-21). The broad spectrum of lymphocyte  reactivity against 
CNS antigens in MS may result from diversification of anti- 
body and T  cell reactivities that occur as the myelin sheath 
suffers progressive damage. Epitope spreading could occur 
regardless  of whether the initial inflammatory response in 
MS is due to direct reactivity against a CNS resident pathogen 
such as a virus (22) or to cross-reactivity between a pathogen- 
encoded epitope and an epitope(s) on a myelin protein (16, 23). 
While T cell specificities appear to change over the course 
of R-EAE, the significance of these events in disease progres- 
sion is not known. Relapses could result from activation of 
T cells specific for endogenous myelin epitopes released during 
the acute phase of disease. Proliferative responses to additional 
encephalitogenic myelin epitopes have been reported to arise 
after the initial acute phase of EAE (16, 24, 25), but the func- 
tional consequences of these responses have not been addressed. 
In the current report, we demonstrate both intermolecular 
and intramolecular epitope spreading in two different models 
of myelin peptide-induced R-EAE. T cells reactive to a sec- 
ondary encephalitogenic PLP epitope (PLP178-191) are found 
in the spleens of mice in which acute EAE was induced by 
T cells reactive with the dominant, non-cross-reactive PLP139- 
151 epitope. T  cell responses  specific for the secondary epi- 
tope are activated as a result of and correlate with the degree 
of acute CNS tissue damage. Most importantly, these T cells 
possess encephalitogenic potential in that they can initiate 
EAE upon secondary adoptive transfer to naive recipients. 
These results strongly support a role for intramolecular epi- 
tope spreading in the relapsing pathogenesis of PLP139-151-in- 
duced EAE. 
Materials  and Methods 
Mice.  Female  SJL/J mice, 6-7 wk old, were purchased from 
Harlan Bioproducts for Science, Inc. (Indianapolis, IN). All mice 
were housed in the Northwestern animal  care  facility  and were main- 
tained on standard laboratory food and water ad lib. 
Antigens/Peptides.  PLP was purified  from bovine  brain according 
to the method of Lees and Sakura (26), and purity was confirmed 
by SDS-PAGE. PLP and MBP Peptides PLP139-151 (HSLGKW- 
LGHPDKF), bovine  PLP178-191B (NTWTTCQSIAAPSK), mouse 
PLP178-191M (NTWTTCQSIAFPSK), PLP104-117 (KTTICGKG- 
LSATVT), and MBP84-104 (VHFFKNIVTPRTPPPSQGKGR) 
were synthesized  (RAMPS  Multiple Peptide  Synthesis  System;  New 
England Nuclear-DuPont, Wilmington, DE). Amino acid com- 
position of these peptides was confirmed by the Northwestern 
University Biotechnology Center. PLP178-191M was insoluble in 
PBS and was dissolved in 0.035 M acetic acid (27). 
Induction of  R-EAE by Active Immunization with PLP and PLP139- 
151.  Mice  were immunized with PLP or PLP139-151 in adjuvant 
as previously described (5). Each mouse received 100 #1 of a CFA 
emulsion containing 200/zg of Mycobacterium tuberculosis H37Ra 
(Difco Laboratories, Inc., Detroit, MI) and 87 #g of PLP139-151 
or 100/zg of  intact PLP subcutaneously  distributed over three spots 
on the flank. Initial clinical signs of disease were usually observed 
between days 12 and 20 after immunization. 
Induction of  R-EAE by Adoptive Transfer  of  PLP139-151- or MBV84- 
104-specific  Lymph  Node  Cells.  Mice were immunized  with 
PLP139-151 or  MBP84-104 according to  previously described 
methods (5, 28). Each mouse received 100/~1 of an IFA emulsion 
containing 200/~g of  M. tuberculosis H37Ra and 25/~g of PLP139- 
151 or 100 #g of  MBP84-104 subcutaneously  distributed over three 
spots on the flank. 7-10 d after immunization,  the inguinal,  brachial, 
and axillary lymph nodes were removed from sensitized donors, 
and single-cell  suspensions were prepared. The cells were adjusted 
to 8  x  106/ml in complete DMEM containing 15-20 #g/ml of 
the appropriate peptide and incubated at 37~  in a humidified at- 
mosphere containing 5% CO2. 4 d later, the cells were washed 
twice with buffered saline solution, counted, resuspended  in 50% 
PercoU (Pharmacia  Biotech, Inc., Piscataway,  NJ), and centrifuged 
at 1,500 rpm for 15 rain at room temperature. Lymphoblasts  were 
removed from the gradient, washed, and injected intraperitoneally 
into naive mice. 
Induction of R-EAE by Adoptive Serial Transfer of PLP139-151- or 
178-191M-specific Splenocytes  from Mice with PLP139-151-induced Dis- 
ease.  40 d after active immunization with PLP139-151 or adop- 
tive transfer of PLP139-151-specific lymph node calls, mice were 
killed and spleens were removed. Spleen cells were cultured with 
PLP139-151 or PLP178-191M as described above. After 4 d of cul- 
ture, 3  x  107-5  x  107 PLP139-151-specific splenocytes or 5  x 
107 PLP178-191M-specific splenocytes  were transferred intraperi- 
toneally into naive recipients. 
Clinical Evaluation.  Mice  were observed drily for clinical signs 
of disease. Mice were scored according to their clinical severity as 
follows: grade 0, no abnormality; grade 1, limp tail; grade 2, limp 
tail and hind limb weakness (waddling gait); grade 3, partial hind 
limb paralysis; grade 4, complete hind limb paralysis; and grade 
5, moribund. The data are plotted as the mean daily clinical score 
for all animals in a particular treatment group. In some instances, 
the mean maximal clinical score per group is given as an indication 
of disease severity. A relapse was defined as an increase of at least 
one full grade in clinical score after the animal had previously im- 
proved at least a full clinical score and had stabilized. 
Histologic Evaluation.  Mice  were anesthetized  with sodium pen- 
tobarbital and killed by total body perfusion through the left ven- 
tricle with chilled 3% glutaraldehyde  in phosphate buffer, pH 7.3. 
Spinal cords were removed by dissection and cut into 1-mm-thick 
cross sections, which were postfixed  in 1% OsO4, dehydrated,  and 
embedded in Epon as previously described (29). Toluidine blue- 
stained sections from 10 to 11 segments per mouse were read blind 
and scored as follows: _+, mild inflammation without demydin- 
ation; 1+, inflammation with focal demyelination; 2", inflamma- 
tion with multiple loci of demyelination; 3% marked inflamma- 
tion with bilateral, converging areas of demyelination; and 4 +, 
extensive bilateral areas of demyelination and remydination. 
Ag-specific Delayed-type Hypersensitivit,/ (DTH).  DTH responses 
were quantitated using a 24-h ear swelling  assay  in mice challenged 
with 5 #g of the relevant Peptide (in 10/~1 saline) as previously 
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SEM. Ear swelling responses were the result of mononuclear cell 
infiltration and showed  typical  DTH kinetics (Le., minimal swelling 
at 4 h, maximal swelling at 24-48 h). 
In Vitro T Cell Proliferation Assay.  T cell proliferative  responses 
were assessed by incorporation of [3H]thymidine. 5  x  105 viable 
draining lymph node (brachial, axillary, and inguinal) cells recov- 
ered from immunized mice were cultured in 96-well flat-bottom 
microculture plates (Falcon Labware, Becton Dickinson and Co., 
Oxnard, CA) in 0.2 ml of DMEM (Gibco Laboratories, Grand Is- 
land, NY) supplemented with 0.75% syngeneic  mouse serum. Al- 
ternatively, 5  x  10  s splenocytes  from adoptive transfer recipients 
were cultured as described above. Triplicate cultures were stimu- 
lated with the indicated doses of antigen and incubated in a hu- 
midified atmosphere of 5% COs. After 72 h, culture wells were 
pulsed with 1.0/zCi of [3H]thymidine  (6.7 Ci/mM, ICN Biomed- 
icals, Inc., Costa Mesa, CA). Cultures were harvested 24 h later 
with a semiautomated cell harvester, and measurements of  radioac- 
tive material were determined in a scintillation counter. Results 
are expressed as (A cpm) = [(mean cpm of antigen-stimulated cul- 
tures)  -  (mean cpm of control cultures)] and/or as stimulation 
indices [(mean cpm of antigen-stimulated cultures)/(mean cpm of 
control cuhures)]. 
Peripheral Tolerance  Induction by Antigen-coupled  Splenocytes.  RBC- 
flee (Tris-NH4Cl-treated) splenocytes  were coupled with antigen 
by the method of Miller et al. (31) using water-soluble 1-ethyl-3- 
(3-dimethylaminopropyl)-carbodiimide  HC1 (ECDI, Calbiochem- 
Behring Corp., La  Jolla, CA). Saline-washed  SJL/J splenocytes  were 
pelleted in 50-ml centrifuge tubes and resuspended to a final con- 
centration of 2.5  x  10  s cells/ml in saline containing 1 mg/ml of 
PLP or PLP139-151. The coupling reaction was initiated by the 
addition of 0.205 ml of freshly prepared ECDI (150 mg/ml in sa- 
line)/ml of cell suspension. Sham-coupled ceils were prepared by 
incubation of splenocytes in saline containing ECDI but no Ag. 
After a 1-h incubation at 4~  the cells were washed three times 
with BSS. At the indicated time relative to active immunization 
with PLP or PLP139-151 or to the adoptive transfer of PLP139- 
151-primed lymph node cells, 5  x  107 Ag-coupled splenocytes 
were injected  intravenously  into the lateral  tail veins  of  recipient mice. 
Statistical Analyses.  Comparisons of the percentage of animals 
showing clinical  disease  between any two groups of  mice were ana- 
lyzed by chi-squared  using Fisher's exact probability. Comparisons 
of the mean day of onset and mean maximal severity  between any 
two groups of mice were analyzed  by the Student's t test. P values 
<0.05  were considered significant. 
Results 
Evidence that PLP139-151  Is the Dominant Encephalitogenic 
PLP Epitope in SJL/J Mice.  Data from our laboratory and 
from others have shown gain of T cell responses to additional 
myelin epitopes and switches in use of MHC class II I-A and 
I-E restriction elements during the course of EAE induced 
with intact MBP (13-15,  17). To approach the possibility of 
similar switches in antigen specificity through the course of 
PLP-induced EAE, we first determined the relative contribu- 
tions of T  cell responses  to the two immunodominant en- 
cephalitogenic PLP epitopes, PLP139-151 (5, 32) and PLP178- 
191 (27), in R-EAE induced with intact PLP. As seen in Fig. 
1, mice receiving sham-coupled ceUs and subsequently primed 
with intact PLP (/1) underwent a normal relapsing-remit- 
ting disease course, with four out of seven (57%) of the mice 
exhibiting disease symptoms by day 17 after immunization. 
Sham-tolerized mice primed with PLP139-151/CFA  (B) also 
underwent a relapsing disease course with 13/14 (93%) of 
the mice affected by day 14 after immunization. The reduced 
incidence and longer time of  onset of  PLP-induced vs PLP139- 
151-induced R-EAE may be due to lower molar concentra- 
tions of encephalitogenic epitopes in the whole PLP prepara- 
tions.  Prior tolerization with intact PLP resulted in total 
protection of the animals from both the initial and rdapsing 
episodes  of PLP-induced clinical  disease  (,4)  and PLP139- 
151-induced disease (data not shown). In contrast, although 
administration of PLP139-151-coupled splenocytes significantly 
delayed the onset of PLP-induced disease, four out of seven 
(57%) of these mice developed clinical disease between days 
31  and 43  after immunization, and these animals experi- 
enced a much milder form of disease (mean maximal disease 
severity [MMS]  =  1.0) as compared with the control group 
(MMS  --  2.5).  Interestingly, the timing of clinical symp- 
toms in the PLP139-151-tolerized group (31-43 d) was similar 
to that seen for the initial relapse in the control group (days 
31-38 in three out of four mice). These results cannot be 
explained by differences in the ability of PLP and PLP139- 
151 to induce tolerance,  since PLP139-151-coupled  spleno- 
cytes effectively inhibited PLP139-151-induced  R-EAE (B). 
We have previously demonstrated that tolerance induced by 
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Figure 1.  Differential  ability  of tolerance  in- 
duced with PLP and PLP139-151 to inhibit  ac- 
tive K-EAE induced with intact PLP or the 
immunodominant  PLP139-151 epitope. Mice 
were tolefized  by the intravenous  injection  of 
5-6 x 107 ECDI-treated splenocytes  coupled 
with either nothing (SHAM-SP), intact  PLP 
(PLP-SP), or  PLP139-151 (PLPIJg-151-SP) 
7-10 d before  induction  of active  K-EAE  with 
either PLP/CFA  (A) or PLP139-151/CFA  (B). 
Animals were followed  for clinical signs of 
disease, expressed as both the mean disease 
severity  and as the incidence  rate, for 55-65 d 
thereafter. *Disease  incidence  significantly  less 
than that of the SHAM-SP injected controls, 
P <0.05: 
77  McRae  et al. antigen-coupled syngeneic splenocytes is antigen specific (33). 
Pretolerance with PLP inhibits the onset of PLP-induced dis-  100 
ease (A) but not MBP-induced R-EAE (34). Collectively, these 
results indicate that the initial acute encephalitogenic response 
in PLP-immunized mice is directed primarily towards PLP139- 
10  151, and that this epitope is immunodominant when corn-  "~ 
pared with PLP178-191 (27), responses to which possibly con- 
tribute to later phases of disease  in mice primed with the  ~ 
intact,  multideterminant PLP molecule. 
Diversification of  Proliferative Responses to PIP Epitopes during  1 
the Course of  Adoptive R-EAE Induced with PLP139-1Sl-specific 
T  Cells.  To examine directly the functional consequences 
of epitope spreading in the pathogenesis of relapsing EAE, 
we reasoned that the reliable relapsing-remitting disease in- 
duced by the major immunodominant PLP139-151  epitope 
would provide an ideal system, in that the initial acute dis- 
ease would be mediated by T  cells specific for a single en- 
cephalitogenic epitope.  R-EAE  was  initiated  by  adoptive 
transfer of lymph node T  cells specific for PLPD9-151, and 
responses to this epitope and to other non-cross-reactive en- 
cephalitogenic PLP (PLP178-191  [27] and PLP104-117  [35]) 
and MBP (MBP84-104 [36]) epitopes were assessed (Fig.  2). 
On day 3 after transfer (before the appearance of acute EAE, 
MMS  ---  0) and on day 17 (concomitant with the peak of 
acute EAE, MMS  =  3.5), splenic proliferative responses to 
PLP139-151,  but not to the other PLP determinants or to 
MBP84-104, could be detected. However, on days 24 and 40 
after transfer (during the remission from the acute disease 
episode), significant splenic proliferative responses were seen 
to both the inducing PLP139-151  epitope and to PLP178- 
191M, which further increased at day 60 after transfer (con- 
comitant with the appearance of a clinical relapse in this group 
of mice, MMS  =  4.0). The development of PLP178-191M- 
specific responses is reproducible in that it was noted in five 
separate experiments in mice with both active and adoptive 
PLP139-151-induced EAE (see also  Table 1).  Interestingly, 
no responses were seen at any time point upon stimulation 
with  the  immunodominant  MBP84-104  epitope or  with  A  100 
PLP104-117.  These results show that intramolecular epitope  g' 
v 
spreading to an endogenous PLP epitope distinct from the 
disease-inducing determinant  occurs during  the course of 
PLP139-151-induced R-EAE.  ~  10 
Peptide Specificity of T  Cell Responses in SJL Mice Primed 
with Intact PLP, PLP139-151, and PLPI78-191M.  PLP is a  g  --, 
276-amino acid structural myelin protein that is highly con- 
served across many species. The sequences of mouse, rat, and 
human PLP molecules are identical but differ from the bo- 
vine  sequence at  four positions,  including  an  alanine  for 
phenylalanine substitution at position 188 (37). To determine 
the fine specificity of T  cell responses to the dominant and 
secondary PLP epitopes and to identify potential affects of 
the substitution at position 188 on T cell recognition of in- 
tact PLP, proliferative assays were performed on PLP, PLP139- 
151, and PLP178-191M-primed lymph node cells  (Fig.  3). 
Before the onset of acute clinical symptoms (10 d after im- 
munization), lymph node T  cells from SJL/J mice primed 
with intact bovine PLP responded well to PLP139-151  and 
Figure 2. 
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course of adoptive PLP139-151-specific  EAE. K-EAE was induced in a 
large group of SJL/J mice via the adoptive  transfer  of 5 x  106 PLPD9- 
151-specific lymph node T cell blasts on day 0. At the indicated times 
(days 3, 17, 24, 40, and 60) after transfer, recipient  splenocytes  were  cul- 
tured with PLP139-151, PLP178-191M, PLP104-117, or MBP84-104 for 
72 h, and 13Hlthymidine  incorporation  determined  over  an additional  24-h 
period. The data are presented as stimulation indices _+ SEM for two to 
three mice  per time  point. The mean  clinical  score  of  the animals sacrificed 
at the various time points is also indicated at the top of the chart. The 
horizontal  line represents  stimulation  index = 3, which is considered  the 
cutoff  for significance. Background  cpm in for all groups were between 
3,833 and 13,392  cpm with the e~ception  of  day 60, which  was 26,142  cpm. 
to PLP178-191B,  but not to PLP178-191M, indicating that 
the alanine at position 188 is critical for T  cell recognition 
of the bovine PLP178-191  epitope. However, after develop- 
ment of acute disease (20 d after immunization), PLP-primed 
mice exhibited proliferative responses to both PLP178-191B 
and PLP178-191M.  T  cells from PLPD9-151-primed mice 
responded only to PLP139-151,  indicating that the epitope 
spreading was not a result of cross-reactivity between CD4 + 
~Z  139-151 
178-191B 
[~ ICZ%P 17S-T91M 
PLP  PLP  PLP139-t51  PLPt78-191M 
Day +10  Day +20  Day +10  Day .10 
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Figure  3.  Peptide  specificity  of T cell responses in SJL/J mice  primed 
with PLP and with the primary (PLP139-151)  and secondary  (PLP178- 
191) encephalitogenic  PLP peptides. Three to four mice per group were 
primed with PLP, PLP139-151, or PLP178-191M  in CFA on day 0. On 
day 10 or 20, draining lymph node cells were cultured with PLPD9-151, 
PLP178-191M, or PLP178-191B  for 72 h, and [3H]thymidine  incorpora- 
tion was determined  over  an additional  24-h  period. The data  are presented 
as stimulation  indices + SEM. The horizontal  line represents  stimulation 
index = 3, which is considered  the cutoff"  for significance. Background 
cpm in for all groups were between 2,382 and 14,944 cpm. 
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the recruited PLP178-191M epitope. Similarly, PLP178-191M 
did not  induce  proliferation  in  several PLP139-151-specific 
T  cell lines and clones (data not shown). Interestingly, T cells 
primed to PLP178-191M  cross-reacted to some extent with 
PLP178-191B, indicating that position 188 is most likely not 
a primary TCR contact residue for all T  cell clones specific 
for PLP178-191M. 
Intermolecular Epitope Spreading  in  MBP84-104-induced 
R-EAE.  To determine if epitope spreading could be identified 
in a  second peptide-induced  model of R-EAE,  disease was 
induced in SJL/J mice by the transfer of MBP84-104-specific 
T cells. Individually, these animals generally display a milder 
acute disease course than recipients  of PLP139-151-specifir 
T  cells and an initial relapse that was more severe than the 
acute disease (Fig. 4 A). T  cell reactivity, as measured by DTH 
in vivo (Fig.  4 B) and by T  cell proliferation  in vitro  (not 
shown),  to the  immunodominant  PLP139-151  epitope de- 
veloped in these mice concomitant  with  the  appearance of 
the  first relapse.  This  has been a  consistent  observation  in 
a number of experiments and is an example of intermolecular 
epitope spreading. The more severe relapse in these mice con- 
current with the development ofT cell reactivity to PLP139- 
151  is consistent with our earlier observation that this pep- 
tide is overwhelmingly the dominant encephalitogenic  my- 
elin  epitope in  the  SJL/J  mouse  (38). 
Functional  Evidence that PLP178-191M-specific  Splenic T Cells 
from Mice with PLP139-151-induced  R-EAE Participate in Re- 
lapsing Pathology.  To further delineate the encephalitogenic 
potential of recruited T  cells with specificity for endogenous 
neuroepitopes, we asked if PLP178-191M-specific T  cells from 
mice with R-EAE induced by PLP139-151  were capable of 
transferring EAE (Table 1). Splenocytes were collected from 
donor  mice  ~40  d  after induction  of both  active  (experi- 
ment 1)  and  adoptive  (experiment  2)  PLP139-151-specific 
EAE.  The  cells  were  activated  in  vitro  with  PLP139-151, 
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Figure  4.  Intermolecular epitope spreading 
during  the relapsing course of MBP84-104- 
specific R-EAE. R-EAE was induced in a large 
group of SJL/J mice via the adoptive transfer 
of 40  x  106 MBP84-104-specific lymph node 
T cell blasts on day 0. (A) A subset of the mice 
(n =  11) was observed for clinical signs of dis- 
ease for 56 d after transfer. (B) At the indi- 
cated times (days 10, 33, and 56) after T cell 
transfer, four to six recipient animals were each 
challenged with 5 #g of the inducing peptide 
(MBP84-104) in the left ear and with 5/~g of 
PLP139-151 in the right ear, and increases in 
ear thickness as a measure of DTH reactivity 
were determined 24 h later. The data are ex- 
pressed as the mean change in ear swelling 
(background swelling in unimmunized controls subtracted) in units of 10 -4 inches +  SEM. Mean background swelling was 4.6 U for MBP84-104 
and 3.8 U for PLP139-151. *DTH responses significantly greater than those of unimmunized controls, P <0.01. 
Table  1.  Serial Transfer of EAE with PLP178-191-specific T Cells from SJL/J Mice Recovered  from Acute PLP139-151-induced 
CNS Damage 
Experiment  Day 40  activation  Disease 
no.  Day 0  inducing  stimulus  peptide*  incidence  MDO*  MMSS 
1  PLP139-151/CFA  PLP139-151  3/3  (100%) II  11.0  _+  1.0  3.7  _+  0.3 
PLP178-191M  3/4  (75%)"  17.7  +_  3.8  2.0  _+  0.6 
MBP84-104  0/2  (0%)  --  -- 
5  x  106 PLP139-151-specific 
T  cells  PLP139-151  3/3  (100%)11  7.7  _+  1.3  4.3  _+  0.3 
PLP178-191M  4/4  (100%) II  14.3  +_  3.4  2.3  +_  0.5 
MBP84-104  0/1  (0%)  -  - 
* On day 40 after recovery from the initial acute phase of clinical disease induced by either immunization  with PLP139-151/CFA  (experiment 1) 
or the transfer of 5 x  106 PLP139-151-specific lymph node T cell blasts (experiment 2), splenic T cells were cultured with the indicated peptides 
for 4 d,  and 5  x  107 cells were transferred to naive, syngeneic recipients. 
* MDO, mean day of onset  +  SEM for clinically affected mice in each group. 
S MMS, mean maximal disease severity +  SEM for clinically affected mice in each group. 
II Significant percentage of the recipient mice displayed clinical disease, P <0.05. 
79  McRae et al. PLP178-191M,  or MBP84-104 and transferred to syngeneic 
naive recipients. All mice (six out of six combined from the 
two experiments) that received splenocytes reactivated with 
the inducing PLP139-151  epitope  exhibited severe clinical 
R-EAE (MMS  =  4.0). Splenocytes stimulated in vitro with 
PLP178-191M transferred disease to seven out of eight (88%) 
recipient mice with a significantly delayed mean day of onset 
when compared with  PLP139-151-activated  cells  (15.7  vs 
9.3 d). Discrepancies in disease onset may result from differ- 
ences in the numbers of antigen-specific T cells transferred. 
However, transfer of equal numbers of activated PLP178-191M 
and PLP139-151-specific  lymph node T  cells suggests that 
PLP178-191M-induced R-EAE is consistently delayed when 
compared with PLP139-151 (data not shown). Recipients of 
the PLF178-191M-activated T cells also exhibited clinical scores 
(MMS  =  2.1)  that were significantly less severe than mice 
receiving PLP139-151-activated splenocytes (MMS  =  4.0). 
Interestingly, splenocytes activated in vitro with MBP84-104 
did not proliferate at any time point tested (Fig. 1) or transfer 
disease to naive recipients (Table 1). Collectively, these results 
suggest that PLP178-191M-specific Thl cells are activated 
by recognition of the endogenous mouse PLP178-191  epi- 
tope during the course of both active and adoptive PLP139- 
151-induced R-EAE, and that these cells are most likely in- 
volved in the relapsing course of disease, as they have potent 
encephalitogenic activity. 
The data in Fig.  1 indicated that responses to secondary 
PLP epitopes, including PLP178-191, played a role in the later 
phases of PLP-induced R-EAE. As a second functional test 
of the role of epitope spreading in the relapsing pathology 
of PLP139-151-induced R-EAE, we asked if tolerance to in- 
tact PLP induced after the acute phase of disease would be 
able to ameliorate clinical relapses. Thus, R-EAE was induced 
in SJL/J mice by active immunization with PLP139-151  in 
CFA. After recovery from the acute phase of disease (day 19 
after priming), 12-13 mice were each tolerized by the intra- 
venous injection of syngeneic splenocytes coupled with in- 
tact PLP and observed for an additional 50 d for the develop- 
ment of clinical relapses.  As seen in Fig. 5,  thirteen out of 
thirteen (100%) of the sham-tolerized mice exhibited clin- 
ical relapses during the observation period, but only five out 
of twelve (42%) of the PLP-tolerized mice relapsed, and these 
relapses were routinely mild (increase of only one clinical grade) 
as compared with those in the sham-tolerized group (increases 
of two or more clinical grades). Similar results were observed 
when mice were tolerized with a crude mouse spinal cord 
homogenate that contains a heterogeneous mixture of neu- 
roantigens (data not shown). Since tolerization with intact 
PLP inhibits T cell responses to both PLP139-151 and PLP178- 
191 (Fig.  1 and additional data not shown) and has no effect 
on induction of active EAE induced with intact MBP (34), 
these results are consistent with a role for PLP178-191-specific 
responses, but  a lack of MBP84-104-specific responses, in 
PLP139-151-induced R.-EAE. 
Peptide-specific Tolerance Prevents the Development of Epitope 
Spreading.  Based on the temporal sequence of appearance 
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Hgure  5.  Effective treatment of clinical relapses in PLP139-151-induced 
R-EAE by specific tolerization with intact PLP after recovery from the 
acute disease. R-EAE was induced in SJI./J mice by active immunization 
with PLP139-151 in CFA. After recovery from the acute phase of disease 
(day 19 after priming), 12-13 mice were each tolerized by the intravenous 
injection of syngeneic splenocytes coupled with intact PLP and observed 
for an additional 50 d for the development of clinical relapses. The data 
are expressed as both the mean disease severity and as the relapse inci- 
dence. *Relapse incidence significantly less than that of the sham SP-in- 
jected controls, P <0.01. 
are consistent with the hypothesis that T  cells with novel 
specifldties are activated after CNS tissue damage has occurred. 
One would thus predict that inhibition of CNS damage may 
prevent priming of T  cells with specificity for endogenous 
self epitopes. Therefore, we asked if induction of PLP139- 
151-specific  tolerance after effector cell transfer but before 
the onset  of the initial  acute clinical episode of adoptive 
PLP139-151-induced1 R-EAE would prevent the development 
of T cell reactivity to the PLP178-191M  epitope. The intra- 
venous injection of PLP139-151-splenocytes (SP) on day 3 after 
adoptive transfer of PLP139-151-activated lymph node cells 
resulted in a significant diminution of clinical R-EAE (Fig. 
6 A).  In addition,  these animals were tested for DTH re- 
sponsiveness  to both the inducing PLP139-151 epitope and 
to PLP178-191M on day 25 after transfer. As seen in Fig. 6 B, 
the four sham-SP-treated mice that developed a severe acute 
phase ofEAE (MMS =  4.5) displayed significant DTH upon 
challenge with either PLP139-151 or PLP178-191M, indicating 
that epitope spreading can also be demonstrated by DTH, 
an in vivo readout of proinflammatory cytokine activity. The 
three out of six mice in the PLP139-151-tolerized group that 
developed very mild EAE (MMS =  1.0) also displayed DTH 
responses to both peptides that were significantly above back- 
ground, but significantly less than those observed in the sham 
SP-treated mice. In contrast, the three tolerant mice that dis- 
played no acute clinical disease symptoms did not respond 
to either the inducing peptide or to PLP178-191M.  Patho- 
logical examination of these groups of animals was also per- 
formed (Fig.  7). The sham-tolerized mice showed the char- 
acteristic changes of EAE, consisting of florid mononuclear 
cell infiltrations in meninges and around parenchymal venules 
in the white matter columns of the spinal  cord. Tolerized 
mice that displayed mild neurological impairment showed 
80  Epitope Spreading in Relapsing Experimental Autoimmune Encephalomyelitis A  CLINICAL  DISEASE COURSE 
4 
[ ~1- SHA  ....  l  416: 
0  5  10  15  20  25 
Days Post  Transfer 
B  DTH RESPONSE-d20 
~  SHAM-SPISICK  ~~/m~U  ' 
- 
=  PLP139-SPISICK 
g 
~  PLP13g-SP/WELL  ~  **  m  PLP139-151 
~J PLP178-191M 
0  10  20  3(: 
Ear Swelling (xlO  -4 in.) +_ SEM 
Figure 6.  Effect ofpeptide-specifictolerance 
on the development of secondary peptide-spe- 
cific DTH responses during the course of adop- 
tive R-EAE induced by transfer of  PLPt39-151- 
specific T  cells. R-EAE was induced  by the 
intravenous transfer of 5  ￿  106 PLP139-151- 
activated T cell blasts on day 0. On day 3, be- 
fore the onset of clinical signs of disease, half 
of the mice were tolerized with PLP139-151- 
coupled splenocytes and half with sham SP. (,4) 
The mean clinical scores for all the mice in the 
two treatment groups and the disease incidence 
are shown.  (B) 25 d after transfer, the recip- 
ient animals were challenged with 5 #g of the 
inducing peptide (PLP139-151) in the left ear 
and with 5 #g of PLP178-191M in the right 
ear, and increases in ear thickness as a measure of DTH reactivity were determined  24 h later. The data are expressed as the mean change in ear swelling 
(background  swelling in unimmunized controls subtracted)  in units  of 10-4 inches  •  SEM. Mean background swelling was 5.1 U  for PLP139-151 
and 2.1 U for PLP178-191M. The data for the PLP139-151-tolerized group is divided into two groups,  those animals showing minimal clinical disease 
(MMS  =  1.0) and those  showing no clinical symptoms  (MMS  =  0). The four clinically affected mice in the sham SP-tolerized  group exhibited  a 
very severe acute clinical phase with MMS  =  4.5.  *DTH responses significantly less than those of the sham  SP controls,  P <0.05;  **P <0.01. 
very minimal tissue involvement, consisting mainly of menin- 
geal inflammatory infiltrates. Occasionally, one could observe 
a focal demyelinating lesion that remained confined to the 
immediate sub-pial  layer of the white matter. In contrast, 
the tolerized animals that showed no clinical symptoms were 
devoid of any CNS lesions. These results indicate that the 
diversification of the immune response normally seen in mice 
with R-EAE correlates with the severity of both clinical and 
histological symptoms during the acute phase of disease. Most 
importantly, epitope spreading can be abrogated by induc- 
tion of specific tolerance to the inducing epitope before acute 
tissue damage. 
Discussion 
Using antigen-specific, peripherally induced immunologic 
tolerance  as a probe for analysis of the neuropathologic T 
cell repertoire, we have previously shown that PLP, not MBP, 
constitutes the immunodominant  neuroantigenic myelin pro- 
tein for the induction of R-EAE in the SJL/J mouse (23). 
Residues 139-151 and 178-191 of the PLP molecule have been 
previously described as being codominant encephalitogenic 
epitopes (27, 32). However, our examination of the contri- 
butions of T  cell responses to these two PLP determinants 
revealed that the majority of immunopathologic reactivity 
during the acute phase of R-EAE in SJL/J mice primed with 
the intact PLP molecule is directed at the PLP139-151 epi- 
tope (Fig. 1). Thus, the current findings indicate that PLP139- 
151 is the dominant immunopathologic epitope of the PLP 
molecule in acute disease and suggest that responses to sec- 
ondary PLP determinants, primarily to PLP178-191, may con- 
tribute to the later phases of disease in mice primed with 
the multideterminant PLP molecule. These results are similar 
to recent findings in the Lewis rat acute EAE system, where 
it has been shown that responses to a secondary enceph'alito- 
genic epitope (MBP87-99)  arise considerably later than re- 
sponses to the dominant MBP68-86 epitope (39),  and that 
MBP-induced clinical disease is more efficiently regulated upon 
tolerization with intact MBP than with the dominant MBP68- 
86 peptide (40,  41). 
The immunodominance of PLP139-151 is also illustrated 
by the fact that active EAE can be induced by immunization 
with this peptide emulsified in CFA (5), whereas induction 
of active EAE with PLP178-191 requires  the additional use 
of pertussis toxin (27). In addition, the clinical course of both 
active and adoptive PLP139-151-induced K-EAE is character- 
ized by a severe acute clinical disease phase and multiple clin- 
ical relapses (Figs. 1 and 5), whereas PLP178-191M-induced 
disease is characterized by a relatively mild acute phase (Table 
1 and additional data not shown). Lastly, analysis of prolifer- 
ative responses in SJL/J mice primed with intact PLP has 
revealed that precursor frequency of PLP139-151-specific T 
cells is three- to fourfold higher than the frequency of PLP178- 
191-specific cells (McRae, B. L., K. M. Nikcevich, and S. D. 
Miller, manuscript in preparation). This is mirrored by the 
increased bulk of proliferative responses observed upon chal- 
lenge of PLP-primed cells with PLP139-151 (Fig.  3). 
T cell specificities appear to change during the course of 
R-EAE (12-15, 42), and this may also occur in MS. Clearly, 
the expression of these additional reactivities  could be due 
to the activation of T  cells specific for endogenous myelin 
epitopes released during the acute phase of CNS damage. Al- 
though some of the specificities that arise have been shown 
to encompass determinants previously defined as encephalito- 
genic when administered with complete adjuvant, the signifi- 
cance of these events in disease  progression (i.e., whether T cells 
spedfic for these recruited epitopes contribute to the immuno- 
pathology of relapsing disease) is largely unknown. 
To determine directly if new antigen specificities  arise during 
the course of R-EAE, we used a model of relapsing EAE 
wherein disease was initiated, either actively or adoptively, 
by T cells specific for the immunodominant  PLPD9-151 epi- 
tope. T cell reactivity to other reported encephalitogenic  PLP 
epitopes and to the major encephalitogenic epitope of MBP 
(MBP84-104) was then assessed. After the initial acute phase 
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histology during the course of adoptive R-EAE induced 
by transfer of PLP139-151-specific T cells. Representative 
animals from the three groups  of mice described in Fig. 
6 B were killed  for histological  examination  26 d after 
initiation of R-EAE by the intravenous  transfer of 5  x 
106  PLP139-151-activated  T  cell blasts. (.4) Section  of 
spinal cord from a sham-tolerized  animal (MMS  =  4.0) 
shows typical mononuclear cell inflammation with exten- 
sive demyelination  and axonal involvement characteristic 
of murine EAE. (B) Section of spinal cord from a PLP139- 
151-SP-tolerized  animal  presenting  with  mild  clinical 
symptoms  (MMS  =  1.0) shows mild inflammation  and 
demyelination. This depicts the most severe  level of  white 
matter involvement seen in these mice. (C) Section of spinal 
cord from a PLP139-151-SP-tolerized animal  exhibiting 
no clinical symptoms  (MMS  =  0) shows clean meninges 
and white matter.  A, B,  and C  are 1-#m-thick, Epon- 
embedded  sections stained with toluidine blue. Original 
magnification:  280. 
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2) and DTH responses (Fig. 6) to the subdominant PLP178- 
191M epitope were detected. Several observations indicate that 
this response is due to  the activation of endogenous host 
T cells. First, there is no cross-reactivity observed at the clonal 
(data not shown) or polyclonal T cell levels (Fig. 3) between 
PLP139-151 and PLP178-191M,  indicating that the response 
is not due to the transferred effector cell population. Second, 
this response is specific for the mouse 178-191 sequence, since 
the cells from mice with disease initiated by PLP139-151 do 
not respond to bovine sequence (PLP178-191B),  which con- 
tains an alanine for phenylalanine substitution at position 188. 
Lastly,  the induction  of PLP139-151-specific  tolerance in 
recipients of PLP139-151-activated T  cells prevents clinical 
disease and the induction of DTH reactivity to PLP178-191M 
(Fig.  6),  indicating that CNS tissue damage must precede 
the development of the recruited response. Interestingly, the 
histopathological severity of the acute phase of PLP139-151-in- 
duced clinical disease roughly correlated with the magnitude 
of the DTH response to PLP178-191M  observed 25 d after 
disease  initiation  (Fig.  6).  Our  ability to prevent epitope 
spreading by tolerizing to the initiating epitope confirms re- 
cent findings that induction of tolerance to glutamate decar- 
boxylase before the onset of insulitis in nonobese diabetic 
mice prevents the development of diabetes and the accom- 
panying immune responses to other pancreatic fl cell antigens 
such as carboxypeptidase H, insulin,  and Hsp65  (17,  18). 
Descriptions of epitope spreading in EAE have largely in- 
volved descriptions of additional proliferative specificities of 
T cells from various lymphoid compartments in mice under- 
going EAE induced by intact MBP (12-14) or an encephalito- 
genic MBP peptide (24). However, it is possible that the emer- 
gence of new specificities  during  R-EAE  may simply be 
secondary events in disease progression that do not influence 
the pathology or clinical expression of disease. For example, 
T cell lines and clones that proliferate to defined encephalito- 
genic epitopes but do not mediate tissue destruction upon 
transfer to naive recipients, presumably because of lack of 
production of proinflammatory cytokines such as lymphotoxin 
(43),  have been described. The only functional evidence to 
date that T  cells specific for secondary epitopes might con- 
tribute  to  clinical  relapses  comes  from  tolerance  studies 
showing that,  after recovery from MBP-induced R-EAE, 
tolerization with mouse spinal cord homogenate (containing 
a heterogeneous mixture of neuroantigens) only, but not with 
MBP, provided an effective means of inhibiting the subse- 
quent clinical relapses (15, 33). These studies provide a direct 
functional indication that the response to that particular my- 
elin protein or epitope contributes to disease pathology. The 
involvement of intermolecular epitope spreading in SJL/J mice 
with R-EAE induced by immunization with MBP84-104 is 
supported directly by the present observation that PLP139- 
151-specific responses appear to contribute to the initial se- 
vere clinical relapse seen in this disease model (Fig.  4). 
In the current study, we took direct approaches to the ques- 
tion of the clinical significance of the development of the 
PLP178-191M-specific T cells in mice with PLP139-151-in- 
duced R-EAE. First, we showed that PLP178-191M-reactive 
cells recovered from the spleens, but not the peripheral lymph 
nodes (data not shown), of mice 40-50 d  after transfer of 
PLP139-151-specific  T  cells  or  active immunization with 
PLP139-151 mediate EAE after in vitro activation and transfer 
to naive recipients (Table 1). It is also significant that PLP178- 
191M-specific responses occurred after both active and adop- 
tive induction of disease, indicating that prolonged periph- 
eral antigenic stimulus from a bolus of PLP139-151/CFA is 
not necessary to invoke epitope spreading. A  second func- 
tional test of the role of epitope spreading in the relapsing 
pathology of PLP139-151-induced K-EAE involved the dem- 
onstration that tolerance induction to determinants within 
the PLP molecule alone after the acute phase of disease was 
sufficient to ameliorate clinical relapses  (Fig.  5).  Taken to- 
gether with the data shown in Figs.  1 and 2, these results 
are compatible with a model wherein responses to PLP178- 
191 and possibly to other secondary or cryptic PLP epitopes 
(intramolecular epitope spreading), but not to the MBP84- 
104 epitope (intermolecular epitope spreading), contribute 
to the relapsing pathology of K-EAE induced with the im- 
munodominant PLP139-151  peptide. 
Collectively, the results demonstrate that new T cell spec- 
ificities to epitopes on the same and/or different myelin pro- 
teins emerge after acute CNS damage in SJL/J mice with 
peptide-induced K-EAE and are capable of mediating clin- 
ical disease. It is possible that local CNS presentation of en- 
dogenous neuroepitopes after acute CNS damage could be 
mediated by infiltrating inflammatory macrophages or by 
endothelial cells and/or astrocytes that have been shown to 
up-regulate expression of MHC class II (10, 44), certain ad- 
hesion molecules (45), and B-7 costimulatory molecules (Nik- 
cevich, K. M., J. A. Bluestone, and S. D. Miller, manuscript 
in preparation) in response to proinflammatory cytokines. Al- 
ternatively, Mamula et al.  (46) recently demonstrated that 
activated B cells can present multiple determinants from a 
single protein in an immunogenic form to overcome T  cell 
tolerance. Antigen presentation by B cells has been postu- 
lated to be important in the pathogenesis of SLE, in which 
T cell-dependent IgG1 autoantibodies are produced against 
small nuclear ribonucleoproteins (46, 47).  Although B cells 
are not necessary for the transfer of K-EAE (48),  the role 
of activated B cells in diversification of autoimmune responses 
by presenting antigen to naive T cells is yet to be determined. 
It is interesting to speculate that epitope spreading may play 
a role in the pathogenesis of chronic and/or relapsing-remit- 
ting human autoimmune diseases such as SLE, rheumatoid 
arthritis, and MS. In MS, responses to a broad spectrum of 
myelin proteins could occur as a result of CNS damage initi- 
ated by T  cell reactivity against a CNS-resident pathogen 
(22)  or by a  cross-reactive response between a pathogen- 
encoded epitope and an epitope on a neuroantigen (16, 23). 
Regardless of the initiating event, the current findings have 
important implications for designing effective antigen-specific 
immunotherapies for treatment of chronic autoimmune dis- 
orders. 
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